pembrolizumab 200mg every 3 weeks

2 trials

Sponsors

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Hiroshima University Hospital

Conditions

Advanced sarcomatoid carcinoma of the lungnon-small cell lung cancer

Phase 2

A single arm confirmatory study of pembrolizumab in patients with previously untreated advanced sarcomatoid carcinoma of the lung

Active, not recruitingJPRN-UMIN000027629

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalAdvanced sarcomatoid carcinoma of the lung

Start: 2017-08-01Target: 20Updated: 2026-06-29

Unknown Phase

Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.

Active, not recruitingJPRN-UMIN000029601

Hiroshima University Hospitalnon-small cell lung cancer

Start: 2017-10-18Target: 30Updated: 2026-06-29